These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 34464379)

  • 1. Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study.
    Chauhan PS; Chen K; Babbra RK; Feng W; Pejovic N; Nallicheri A; Harris PK; Dienstbach K; Atkocius A; Maguire L; Qaium F; Szymanski JJ; Baumann BC; Ding L; Cao D; Reimers MA; Kim EH; Smith ZL; Arora VK; Chaudhuri AA
    PLoS Med; 2021 Aug; 18(8):e1003732. PubMed ID: 34464379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
    Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.
    Zhang R; Zang J; Xie F; Zhang Y; Wang Y; Jing Y; Zhang Y; Chen Z; Shahatiaili A; Cai MC; Zhao Z; Du P; Jia S; Zhuang G; Chen H
    J Urol; 2021 Oct; 206(4):873-884. PubMed ID: 34061567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary Tumor DNA MRD Analysis to Identify Responders to Neoadjuvant Immunotherapy in Muscle-invasive Bladder Cancer.
    Zhang R; Zang J; Jin D; Xie F; Shahatiaili A; Wu G; Zhang L; Wang L; Zhang Y; Zhao Z; Du P; Jia S; Fan J; Zhuang G; Chen H
    Clin Cancer Res; 2023 Oct; 29(20):4040-4046. PubMed ID: 37535065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA.
    Dudley JC; Schroers-Martin J; Lazzareschi DV; Shi WY; Chen SB; Esfahani MS; Trivedi D; Chabon JJ; Chaudhuri AA; Stehr H; Liu CL; Lim H; Costa HA; Nabet BY; Sin MLY; Liao JC; Alizadeh AA; Diehn M
    Cancer Discov; 2019 Apr; 9(4):500-509. PubMed ID: 30578357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients.
    Chauhan PS; Shiang A; Alahi I; Sundby RT; Feng W; Gungoren B; Nawaf C; Chen K; Babbra RK; Harris PK; Qaium F; Hatscher C; Antiporda A; Brunt L; Mayer LR; Shern JF; Baumann BC; Kim EH; Reimers MA; Smith ZL; Chaudhuri AA
    NPJ Precis Oncol; 2023 Jan; 7(1):6. PubMed ID: 36658307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine.
    Pellini B; Pejovic N; Feng W; Earland N; Harris PK; Usmani A; Szymanski JJ; Qaium F; Mudd J; Petty M; Jiang Y; Singh A; Maher CA; Henke LE; Park H; Ciorba MA; Kim H; Mutch MG; Pedersen KS; Tan BR; Hawkins WG; Fields RC; Chaudhuri AA
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer.
    Teo MTW; Dyrskjøt L; Nsengimana J; Buchwald C; Snowden H; Morgan J; Jensen JB; Knowles MA; Taylor G; Barrett JH; Borre M; Ørntoft TF; Bishop DT; Kiltie AE
    Ann Oncol; 2014 Apr; 25(4):877-883. PubMed ID: 24623370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients.
    van Hoogstraten LMC; van Gennep EJ; Kiemeney LALM; Witjes JA; Voskuilen CS; Deelen M; Mertens LS; Meijer RP; Boormans JL; Robbrecht DGJ; Beerepoot LV; Verhoeven RHA; Ripping TM; ; van Rhijn BWG; Aben KKH; Hermans TJN
    World J Urol; 2022 Jan; 40(1):111-118. PubMed ID: 34585294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.
    Necchi A; Raggi D; Gallina A; Ross JS; Farè E; Giannatempo P; Marandino L; Colecchia M; Lucianò R; Bianchi M; Colombo R; Salonia A; Gandaglia G; Fossati N; Bandini M; Pederzoli F; Capitanio U; Montorsi F; de Jong JJ; Dittamore R; Liu Y; Davicioni E; Boormans JL; Briganti A; Black PC; Gibb EA
    Eur Urol; 2020 Jun; 77(6):701-710. PubMed ID: 32165065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Muscle-Invasive Bladder Cancer Patient With High Tumor Mutational Burden and RB1 Mutation Achieved Bladder Preservation Following Chemotherapy Combined With Immunotherapy: A Case Report.
    Cao C; Fu Z; Liu Y; Zhou A; Wang J; Shou J
    Front Immunol; 2021; 12():684879. PubMed ID: 34177933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal Residual Disease Detection with Urine-derived DNA Is Prognostic for Recurrence-free Survival in Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer Treated with Nadofaragene Firadenovec.
    Narayan VM; Tholomier C; Mokkapati S; Martini A; Caruso VM; Goudarzi M; Mazzarella BC; Phillips KG; Bicocca VT; Levin TG; Yla-Herttuala S; McConkey DJ; Dinney CPN
    Eur Urol Oncol; 2024 Oct; ():. PubMed ID: 39406613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.
    Szabados B; Kockx M; Assaf ZJ; van Dam PJ; Rodriguez-Vida A; Duran I; Crabb SJ; Van Der Heijden MS; Pous AF; Gravis G; Herranz UA; Protheroe A; Ravaud A; Maillet D; Mendez MJ; Suarez C; Linch M; Prendergast A; Tyson C; Stanoeva D; Daelemans S; Rombouts M; Mariathasan S; Tea JS; Mousa K; Sharma S; Aleshin A; Banchereau R; Castellano D; Powles T
    Eur Urol; 2022 Aug; 82(2):212-222. PubMed ID: 35577646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From Detection to Cure - Emerging Roles for Urinary Tumor DNA (utDNA) in Bladder Cancer.
    Linscott JA; Miyagi H; Murthy PB; Yao S; Grass GD; Vosoughi A; Xu H; Wang X; Yu X; Yu A; Zemp L; Gilbert SM; Poch MA; Sexton WJ; Spiess PE; Li R
    Curr Oncol Rep; 2024 Aug; 26(8):945-958. PubMed ID: 38837106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.
    Plimack ER; Dunbrack RL; Brennan TA; Andrake MD; Zhou Y; Serebriiskii IG; Slifker M; Alpaugh K; Dulaimi E; Palma N; Hoffman-Censits J; Bilusic M; Wong YN; Kutikov A; Viterbo R; Greenberg RE; Chen DY; Lallas CD; Trabulsi EJ; Yelensky R; McConkey DJ; Miller VA; Golemis EA; Ross EA
    Eur Urol; 2015 Dec; 68(6):959-67. PubMed ID: 26238431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.
    Necchi A; Anichini A; Raggi D; Briganti A; Massa S; Lucianò R; Colecchia M; Giannatempo P; Mortarini R; Bianchi M; Farè E; Monopoli F; Colombo R; Gallina A; Salonia A; Messina A; Ali SM; Madison R; Ross JS; Chung JH; Salvioni R; Mariani L; Montorsi F
    J Clin Oncol; 2018 Dec; 36(34):3353-3360. PubMed ID: 30343614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.
    Tarazona N; Gimeno-Valiente F; Gambardella V; Zuñiga S; Rentero-Garrido P; Huerta M; Roselló S; Martinez-Ciarpaglini C; Carbonell-Asins JA; Carrasco F; Ferrer-Martínez A; Bruixola G; Fleitas T; Martín J; Tébar-Martínez R; Moro D; Castillo J; Espí A; Roda D; Cervantes A
    Ann Oncol; 2019 Nov; 30(11):1804-1812. PubMed ID: 31562764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial.
    Hinsenveld FJ; Noordman BJ; Boormans JL; Voortman J; van Leenders GJLH; van der Pas SL; van Beek SC; Oprea-Lager DE; Vis AN
    BMC Cancer; 2021 Oct; 21(1):1161. PubMed ID: 34715822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma.
    Nordentoft I; Lindskrog SV; Birkenkamp-Demtröder K; Gonzalez S; Kuzman M; Levatic J; Glavas D; Ptashkin R; Smadbeck J; Afterman D; Lauterman T; Cohen Y; Donenhirsh Z; Tavassoly I; Alon U; Frydendahl A; Rasmussen MH; Andersen CL; Lamy P; Knudsen M; Polak P; Zviran A; Oklander B; Agerbæk M; Jensen JB; Dyrskjøt L
    Eur Urol; 2024 Oct; 86(4):301-311. PubMed ID: 38811314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
    Becker REN; Meyer AR; Brant A; Reese AC; Biles MJ; Harris KT; Netto G; Matoso A; Hoffman-Censits J; Hahn NM; Choi W; McConkey D; Pierorazio PM; Johnson MH; Schoenberg MP; Kates MR; Baras A; Bivalacqua TJ
    Eur Urol; 2021 Mar; 79(3):364-371. PubMed ID: 32814637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.